Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | TRVI Trevi Therapeutics, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $15.04 -5.3% | $16.00 -2.5% |
| StockIQ Score | 50C- Moderate Risk: Medium | 35F Weak Risk: High |
| Technical | 39F | 13F |
| Fundamental | 46D+ | 35F |
| Growth | 57C | 50C- |
| Fair Value | 38F | 38F |
| News | 98A+ | 50C- |
| Quality | — | 50C- |
| Risk | 48D+ | 40D |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Trevi Therapeutics (TRVI) outperforms Ascentage Pharma (AAPG) in investor confidence and overall rating, scoring 49 versus 37 and holding a "MODERATE" rating compared to "WEAK." TRVI also leads in technical (32 vs. 18) and fundamental (46 vs. 35) scores, though both share the same valuation score of 38. AAPG has a slight edge in growth (50 vs. 57), but TRVI’s broader strengths make it stronger overall.